These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Liver transplantation in a patient with unresectable colorectal liver metastases -- a case report. Hrehoreţ D; Alexandrescu S; Braşoveanu V; Grigorie R; Zielinski C; Popescu I Chirurgia (Bucur); 2013; 108(5):719-24. PubMed ID: 24157119 [TBL] [Abstract][Full Text] [Related]
43. [Chemotherapy in colorectal carcinoma. From "one-drug-show" to therapeutic multiplicity]. Köster W; Stahl M; Wilke H MMW Fortschr Med; 2000 Aug; 142(31-32):30-2. PubMed ID: 10992764 [TBL] [Abstract][Full Text] [Related]
44. New possibilities in chemotherapy for colorectal cancer. Bekradda M; Cvitkovic E Ann Oncol; 1999; 10 Suppl 6():105-11. PubMed ID: 10676561 [No Abstract] [Full Text] [Related]
45. Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP. Kobayashi Y; Komatsu Y; Yuki S; Fukushima H; Sasaki T; Iwanaga I; Uebayashi M; Okuda H; Kusumi T; Miyagishima T; Sogabe S; Tateyama M; Hatanaka K; Tsuji Y; Nakamura M; Konno J; Yamamoto F; Onodera M; Iwai K; Sakata Y; Abe R; Oba K; Sakamoto N Future Oncol; 2015; 11(4):617-27. PubMed ID: 25686117 [TBL] [Abstract][Full Text] [Related]
46. Recent developments on the integration of biologic agents with cytotoxic chemotherapy in the treatment of advanced colorectal cancer. Chu E Clin Colorectal Cancer; 2008 Dec; 7 Suppl 2():S46. PubMed ID: 19064405 [No Abstract] [Full Text] [Related]
47. The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer. Matsushita H; Tsuboi K; Honda I; Kato N; Okochi O; Kobayashi D; Hattori M Gan To Kagaku Ryoho; 2009 May; 36(5):797-801. PubMed ID: 19461180 [TBL] [Abstract][Full Text] [Related]
49. Role of oral chemotherapy in colorectal cancer. Donehower RC Oncology (Williston Park); 2000 Nov; 14(11A):243-5. PubMed ID: 11195416 [TBL] [Abstract][Full Text] [Related]
50. FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancer. Giusti RM; Cohen MH; Keegan P; Pazdur R Oncologist; 2009 Mar; 14(3):284-90. PubMed ID: 19282350 [TBL] [Abstract][Full Text] [Related]
51. Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy. Lee JJ; Kim TM; Yu SJ; Kim DW; Joh YH; Oh DY; Kwon JH; Kim TY; Heo DS; Bang YJ; Kim NK Jpn J Clin Oncol; 2004 Jul; 34(7):400-4. PubMed ID: 15342667 [TBL] [Abstract][Full Text] [Related]
52. OPTIMOX1 in advanced colorectal cancer: lack of evidence for a stop-and-go strategy. Rosa DD; Ismael GF; de Azambuja E; Braga S; Cardoso F; Bleiberg H J Clin Oncol; 2006 Nov; 24(32):5176-7; author reply 5177. PubMed ID: 17093286 [No Abstract] [Full Text] [Related]
53. Intensive chemotherapy of metastatic colorectal cancer: weighing between safety and clinical efficacy: Evaluation of Masi G, Loupakis F, Salvatore L, et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 2010;11:845-52. Bruera G; Ricevuto E Expert Opin Biol Ther; 2011 Jun; 11(6):821-4. PubMed ID: 21545334 [TBL] [Abstract][Full Text] [Related]
54. Chemotherapy of metastatic bowel cancer. Ross PJ; Cunningham D Br J Hosp Med; 1996 Mar 6-19; 55(5):263-6. PubMed ID: 8777518 [No Abstract] [Full Text] [Related]
55. FOLFOX-4 regimen with concomitant highly active antiretroviral therapy in metastatic colorectal cancer HIV-infected patients: a report of five cases and review of the literature. Berretta M; Di Benedetto F; Bearz A; Simonelli C; Martellotta F; Del Ben C; Berretta S; Spina M; Tirelli U Cancer Invest; 2008 Jul; 26(6):610-4. PubMed ID: 18584352 [TBL] [Abstract][Full Text] [Related]
56. Is there a role for mitomycin C in metastatic colorectal cancer? Dimou A; Syrigos KN; Saif MW Expert Opin Investig Drugs; 2010 Jun; 19(6):723-35. PubMed ID: 20433364 [TBL] [Abstract][Full Text] [Related]
57. Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases. Kandutsch S; Klinger M; Hacker S; Wrba F; Gruenberger B; Gruenberger T Eur J Surg Oncol; 2008 Nov; 34(11):1231-6. PubMed ID: 18272318 [TBL] [Abstract][Full Text] [Related]
58. Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis. Hong J; Han SW; Ham HS; Kim TY; Choi IS; Kim BS; Oh DY; Im SA; Kang GH; Bang YJ; Kim TY Cancer Chemother Pharmacol; 2011 Jun; 67(6):1323-31. PubMed ID: 20734048 [TBL] [Abstract][Full Text] [Related]
59. Danitumumab adjunctive therapy. No place in either first- or second-line treatment of metastatic colorectal cancer. Prescrire Int; 2013 May; 22(138):120. PubMed ID: 23819169 [TBL] [Abstract][Full Text] [Related]
60. Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability. Lévi F; Karaboué A; Gorden L; Innominato PF; Saffroy R; Giacchetti S; Hauteville D; Guettier C; Adam R; Bouchahda M Cancer Chemother Pharmacol; 2011 Feb; 67(2):339-48. PubMed ID: 20401611 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]